Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent β-thalassemia using real-world criteria

Khaled Musallam, Maria Domenica Cappellini, Antonis Kattamis, Kevin Kuo, Sujit Sheth, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Christopher Westcott, Ali Taher

Blood (2025) 146 (Supplement 1): 1139.

https://doi.org/10.1182/blood-2025-1139

Published: 2025

Journal Articles

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

Ali Taher, Khaled Musallam, Maria Domenica Cappellini, Maria Dimopoulou, Antonis Kattamis, Silverio Perrotta, Paolo Ricchi, Manuela Balocco, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Veronika Pozharskaya, John Porter

Blood (2025) 146 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2025-4695

Published: 2025

Journal Articles

A phase 2 study of luspatercept in adults and adolescents with α-thalassemia: Findings from the dose-confirmation cohort in adolescents

Yongrong Lai, Meng-Yao Lu, Ying Zhao, Antonis Kattamis, Gian Luca Forni, Kitty Formentin, Pablo Gurman, Mingzhao Gao, Loyse Felber Medlin, Patricia Martin-Regueira, Vincent Jaquet, Vip Viprakasit

Blood (2025) 146 (Supplement 1): 4689.

https://doi.org/10.1182/blood-2025-4689

Published: 2025

Journal Articles

Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial

John B. Porter, Maria Domenica Cappellini, Kevin H.M. Kuo, Maria Dimopoulou, Marta Reverte, Loyse Felber Medlin, Shweta Sharma, Kefeng Wang, Jennie Zhang, Ali T. Taher

Blood (2024) 144 (Supplement 1): 2475.

https://doi.org/10.1182/blood-2024-200157

Published: 2024

Journal Articles

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Kevin H.M. Kuo, Pranee Sutcharitchan, Ping Chong Bee, Lee Ping Chew, Soo Min Lim, Ai Sim Goh, Sadanand Vodala, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Martina Perin, Luciana Moro Bueno, Thomas D Coates, Vip Viprakasit

Blood (2023) 142 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2023-174082

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Maria Domenica Cappellini, Ali T Taher, Vip Viprakasit, Pencho Georgiev, Kevin H.M. Kuo, Natalia Holot, Valérie Vilmont, Loyse Felber Medlin, Wen-Ling Kuo, Yinzhi Lai, Luciana Moro Bueno, Sujit Sheth

Blood (2023) 142 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2023-174089

Published: 2023

Journal Articles

Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study

Khaled M Musallam, Ali T Taher, Antonis Kattamis, Maria Domenica Cappellini, Jennifer Lord-Bessen, Mrudula Glassberg, Christopher Pelligra, Shien Guo, Loyse Felber Medlin, Luciana Moro Bueno, Kevin H.M. Kuo

Blood (2023) 142 (Supplement 1): 2474.

https://doi.org/10.1182/blood-2023-173366

Published: 2023

Journal Articles

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Sujit Sheth, Olivier Hermine, Ali T. Taher, Kevin H.M. Kuo, John B. Porter, Antonio Piga, Thomas D. Coates, Antonis Kattamis, Loyse Felber Medlin, Wen-Ling Kuo, Natalia Holot, Maria Domenica Domenica Cappellini

Blood (2022) 140 (Supplement 1): 1946–1948.

https://doi.org/10.1182/blood-2022-157511

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent β-thalassemia using real-world criteria

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

A phase 2 study of luspatercept in adults and adolescents with α-thalassemia: Findings from the dose-confirmation cohort in adolescents

Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only